Table 2.
Association between FAP mRNA expression and clinicopathological features in the TCGA cohort.
| Clinical features | Low FAP expression | High FAP expression | p | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Gender (n = 591) | Female (n = 271) | 133 (49.1%) | 138 (50.9%) | 0.81 |
| Male (n = 320) | 154 (48.1%) | 166 (51.9%) | ||
| AJCC stages (n = 571)* | Stage I + II (n = 316) | 167 (52.8%) | 149 (47.2%) | 0.02 |
| Stage III + IV (n = 255) | 111 (43.5%) | 144 (56.5%) | ||
| Microsatellite instability (n = 115)* | MSI (n = 11) | 7 (63.6%) | 4 (36.4%) | 0.42 |
| MSS (n = 104) | 53 (51.0%) | 51 (49.0%) | ||
| CRC subtyping (n = 556)* | CMS1 (n = 97) | 36 (37.1%) | 61 (62.9%) | <0.001** |
| CMS2 (n = 170) | 129 (75.9%) | 41 (24.1%) | ||
| CMS3 (n = 94) | 66 (70.2%) | 28 (29.8%) | ||
| CMS4 (n = 195) | 17 (8.7%) | 178 (91.3%) | ||
| CRC location (n = 597)* | Cecum (n = n = 106) | 56 (52.8%) | 50 (47.2%) | 0.4 |
| Ascending colon (n = 86) | 31 (36.0%) | 55 (64.0%) | ||
| Descending colon (n = 20) | 9 (45.0%) | 11 (55.0%) | ||
| Transverse colon (n = 38) | 20 (52.6%) | 18 (47.4%) | ||
| Sigmoid colon (n = 155) | 75 (48.4%) | 80 (51.6%) | ||
| Hepatic flexure (n = 26) | 12 (46.2%) | 14 (53.8%) | ||
| Splenic flexure (n = 7) | 4 (57.0%) | 3 (43.0%) | ||
| Rectosigmoid junction (n = 49) | 24 (49.0%) | 25 (51.0%) | ||
| Rectum (n = 110) | 60 (55.0%) | 50 (45.0%) | ||
*
Patients with data not available, unknown, and discrepancies.
**
Statistical power >70% (estimated by bootstrapping).
All 2 × 2 contingency tables were analyzed with Fisher exact tests. All others by χ2 test.